Fig. 5.

Siglec-15 blockage prevents secondary metastases from bone lesions. (A) Bone lesions more readily give rise to secondary metastases to multiple organs. (B) Secondary metastases of PBS-treated (Top, n = 9) and 5G12-treated (Bottom, n = 9) 4T1 bone tumors were detected by bioluminescence imaging after dissection. (C) Heat map of ex vivo BLI intensity and status of metastatic involvement in tissues from the 4T1 tumor model mice treated with PBS and 5G12. Each column represents an individual animal, and each row represents a type of tissue. The presence of metastasis was defined as the presence of BLI signal above 30 counts/pixel under 60 s exposure time. Multisite metastases were defined as the metastatic involvement of at least two tissues. P-values were determined by Fisher’s exact test on the frequency of metastatic involvement while by the Mann−Whitney test of the metastatic burden. (D) The ratio of multi-site metastasis of 4T1 tumor model mice. (E) Secondary metastases of PBS-treated (Top, n = 10) and 5G12-treated (Bottom, n = 10) EO771 bone tumors were detected by bioluminescence imaging after dissection. (F) Heat map of ex vivo BLI intensity and status of metastatic involvement in tissues from EO771 tumor model mice treated with PBS and 5G12 as described in (C). (G) The ratio of multi-site metastasis of EO771 tumor model mice.